Intranasal Drug Delivery: A US Market Report
San Jose, California (Vocus/PRWEB) January 20, 2011
GIA announces the release of a comprehensive US market report on intranasal drug delivery products. The US market for intranasal drug delivery products is forecast to reach US$4.4 billion by the year 2015. Key factors driving market growth include quicker drug action, less frequent dosages when compared to oral drugs, greater patient compliance and outcomes, in addition to being cost effective and safe. Other growth drivers include expansion in therapeutic applications, and need for product differentiation.
Intranasal drug delivery has evolved as an important form of drug delivery in the recent years and is all set to create significant milestones in the pharmaceutical industry, driven largely by its ability to cure local infections and chronic allergies. Scientists and researchers are finally waking up to the benefits and numerous advantages of utilizing the nose as an en-route for escorting drugs to the target disease site. The unique vascular structure of the nose makes this organ especially accessible for delivery of small molecule drugs and biologics, a fact, which only recently is being fully appreciated by the medical community. Leveraging conducive healthcare and demographic trends, intranasal drug delivery stands poised to eat into the popularity of other dominant drug delivery methods, such as oral and parenteral, among others.
The popularity, and universal acceptance of intranasal drug administration by doctors and researchers alike is largely due to the proffered potential of the technique’s efficiency in delivering systemic drugs. This is of special significance, given the convergence of technology and consumer demographic trends, which highlight the emergence and popularity of self-administration of drugs for personal management and control of chronic conditions. The systemic drug delivery market is presently experiencing unbridled growth. Topical therapeutics, such as therapies for nasal congestion, allergic rhinitis, and other infections, account for a major share of the Intranasal drug delivery market. However, as the market for locally acting drugs matures, the acceleration in growth is expected to tame down in the short to medium term. Maturity of the topical drug delivery market is also a factor playing an instrumental role in igniting the interest surrounding intranasal drug administration.
In addition to treating common ailments such as nasal congestion, application of intranasal drug administration is expanding to include treatment of osteoporosis, pain management, vitamin B12 deficiency, smoking cessation, migraines, and nocturnal enuresis. Technology developments in the area of designing dry powder inhalation devices, for instance, are stepping up interest in intranasal drug delivery. Incremental developments effected in the area of powder particle formulation, and engineering, and device architecture is helping powder inhalers to fiercely compete with other delivery techniques, which escort active drug agents via the lungs. Another noteworthy area of success for intranasal drug delivery is Vaccination.
Allergic Infections represents the largest therapeutic area of the intranasal drug delivery, as stated by the new market research report on intranasal drug delivery. However, growth in the market would be fuelled by applications in Analgesics therapeutic area. Increase in the demand for intranasal osteoporosis and analgesic drugs, is expected to be the major growth driver in the market. Osteoporosis is also an important application area for intranasal drug delivery. As such, future growth of the intranasal osteoporosis drugs market is highly dependent upon regulatory outcomes. Overall, new therapeutic areas are emerging for intranasal drugs. Some of the major emerging therapeutic application areas for intranasal drugs include sexual dysfunction and Vitamin B12 deficiency. In addition, most of the growth is expected to be derived from new therapeutic applications, such as vaccines. The use of intranasal drug delivery in Vaccinations is projected to witness a compounded annual growth rate of 17.9% during the analysis period.
Major players profiled in the report include Aegis Therapeutics LLC, AptarGroup Inc., AstraZeneca Plc., Bayer Consumer Care, GlaxoSmithKline Plc, Ikano Therapeutics Inc., Javelin Pharmaceuticals Inc, Marina Biotech Inc., Novartis AG, OptiNose AS, among others.
The research report titled “Intranasal Drug Delivery: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the intranasal drug delivery market, current market trends, key growth drivers, recent product introductions, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for intranasal drug delivery products (prescription drugs) for the years 2007 through 2015 by the following therapeutic areas - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Also, a seven-year (2000-2006) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Intranasal_Drug_Delivery_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/